<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Alexander, Walter</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Krzakowski, Maciej</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Phase 3 Study of Vinflunine versus Docetaxel in Patients with Advanced Non-Small Cell Lung Cancer Previously Treated with a Platinum-Containing Regimen</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2007</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2007-08-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">27-29</style></pages><abstract><style  face="normal" font="default" size="100%">This article discusses a phase 3 Study of vinflunine Versus docetaxel in patients with advanced non-small cell lung cancer (NSCLC) previously treated with a platinum-containing regimen, as well as results from the IRIS Study, and the use of surgery alone or surgery plus induction paclitaxel/carboplatin chemotherapy in early stage NSCLC.</style></abstract><number><style face="normal" font="default" size="100%">3</style></number><volume><style face="normal" font="default" size="100%">7</style></volume></record></records></xml>